Cancer Family
Liver Epithelial Neoplasm
CI-CAN-00000217Explore in graph →
Non-malignant784 active trials14 approved drugs17 evidence items
- NCIt
- C7106
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000217Explore in graph →
Clinical trials
3,372 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02109146 | Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma | completed | Phase 3 | 332 | Zhejiang UniversityOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT03776123 | Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients | completed | — | 347 | IpsenINDUSTRY | 1 | May 29, 2024 | clinicaltrials |
| NCT04842565 |
| cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria |
| completed |
| Phase 2 |
| 20 |
| Fudan UniversityOTHER |
| 1 |
| May 22, 2024 |
| clinicaltrials |
| NCT04152343 | An Intraoperative Guidance Platform for Radio Frequency Ablation | completed | N/A | 62 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT06420791 | The Dual Impact of Cirrhosis on Transplantation for Hepatocellular Carcinoma：a Two-center Retrospective Cohort Study in China | completed | — | 1 | Xiao XuOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT04562428 | The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial | completed | Phase 4 | 10 | China Medical University HospitalOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06409507 | Research and Application for New Clinical Diagnosis and Treatment System for HBV Related HCC Liver Transplantation | completed | — | 178 | First People's Hospital of HangzhouOTHER | 0 | May 10, 2024 | clinicaltrials |
| NCT00617981 | Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC) | completed | Phase 3 | 701 | ImunonINDUSTRY | 11 | May 3, 2024 | clinicaltrials |
| NCT05040438 | Natural Killer (NK) Cell Therapy in Locally Advanced HCC | completed | Phase 2 | 17 | Vaxcell Bio, Co., Ltd.INDUSTRY | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06390228 | Impact of Hepatectomy on HCC Recurrence(HCC) | completed | — | 197 | Anhui Medical UniversityOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT02705105 | Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 114 | Kyowa Kirin, Inc.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT04444167 | A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 59 | AkesoINDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT04728321 | A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma | completed | Phase 2 | 32 | AkesoINDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT02508467 | A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma | completed | Phase 1 | 146 | Blueprint Medicines CorporationINDUSTRY | 12 | Apr 12, 2024 | clinicaltrials |
| NCT05823584 | Cell-free DNA From Junction of Hepatitis B Virus Integration in HCC Patients for Monitoring Post-resection Recurrence | completed | — | 207 | TCM Biotech International Corp.INDUSTRY | 1 | Apr 10, 2024 | clinicaltrials |
| NCT03201458 | Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer | completed | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2024 | clinicaltrials |
| NCT06313047 | Pharmacogenetic of Doxorubicin in HCC. | completed | — | 81 | Rehab WeridaOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT02273362 | Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver | completed | Phase 1 / Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06315101 | Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China | completed | — | 142 | Guangzhou University of Chinese MedicineOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT04451603 | LiverMultiScan Analysis of MRI Scans in HCC | completed | — | 21 | National Cancer Centre, SingaporeOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT05239507 | OREIOS International Study(OREIOS) | completed | — | 1,127 | AstraZenecaINDUSTRY | 11 | Mar 13, 2024 | clinicaltrials |
| NCT06030895 | Sorafenib In Egyptian Patients With Hepatocellular Carcinoma. | completed | N/A | 100 | Damanhour UniversityOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06298123 | Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling | completed | — | 304 | Chen XiaopingOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT04618367 | HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT | completed | N/A | 30 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04627012 | Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma | completed | — | 600 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT02182687 | Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant(SBRTvsTACE) | completed | Phase 2 | 60 | Lahey ClinicOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT04103398 | TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma(TREAT) | completed | Phase 3 | 162 | Sun Yat-sen UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06041425 | The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE | completed | Phase 4 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT02859753 | Comparison of Response and Recurrence Rates Following Percutaneous Microwave Coagulation Therapy Versus Percutaneous Radiofrequency Ablation(Thermoablation) | completed | N/A | 35 | Centre Hospitalier Universitaire DijonOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT03047603 | Evaluation of Diagnostic Efficiency of PIVKA-II and Other Tumor Markers in HCC | completed | — | 4,005 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06265883 | Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT | completed | — | 205 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06261138 | Survival Analysis: TACE vs. Combination Therapy in HCC | completed | — | 279 | Zhejiang UniversityOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT03893695 | Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC) | completed | Phase 1 / Phase 2 | 20 | Suzhou Kintor Pharmaceutical Inc,INDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT06245798 | Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension | completed | — | 3,000 | Tang-Du HospitalOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT02695628 | [18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer | completed | Phase 2 | 5 | Stanford UniversityOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06233708 | Association Between Pre-op Non-Selective Beta-Blockers and Hepatocellular Carcinoma Recurrence Post-Liver Transplant | completed | — | 2,092 | Asan Medical CenterOTHER | 0 | Jan 31, 2024 | clinicaltrials |
| NCT06199297 | Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma | completed | — | 188 | Sun Yat-sen UniversityOTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT02650271 | Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC | completed | Phase 3 | 240 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT02329860 | Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP) | completed | Phase 3 | 400 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 22, 2024 | clinicaltrials |
| NCT03535259 | Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma(SIRAHCC) | completed | Phase 2 | 86 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT01004978 | Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | completed | Phase 3 | 235 | National Cancer Institute (NCI)NIH | 1 | Jan 3, 2024 | clinicaltrials |
| NCT01825603 | ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer | completed | Phase 1 | 17 | University of NebraskaOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT03230318 | Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma(FIDES-01) | completed | Phase 2 | 148 | Basilea PharmaceuticaINDUSTRY | 11 | Dec 19, 2023 | clinicaltrials |
| NCT00683631 | TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)(TheraSphere) | completed | — | 183 | University of LouisvilleOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT01624285 | Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer | completed | Phase 2 | 20 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT03006926 | A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma | completed | Phase 1 | 104 | Eisai Co., Ltd.INDUSTRY | 7 | Dec 13, 2023 | clinicaltrials |
| NCT05007548 | to Assess the Accuracy and Reliability of the Ga68-Dolacga Positron Emission Tomography Compared to Computer Tomography Volumetry and Indocyanine Green Retention Test for Measurement of Liver Reserve | completed | Phase 2 | 30 | National Atomic Research Institute, TaiwanOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT00355238 | A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer | completed | Phase 2 | 137 | Bristol-Myers SquibbINDUSTRY | 8 | Dec 1, 2023 | clinicaltrials |
Data updated 23 days agoSource updated May 29, 2024source: clinicaltrials